Baidu
map

Cell Metab:颠覆认知!衰老会促进癌症复发!

2018-04-11 Michael,Yui 转化医学网

过去的理论认为,细胞衰老主要发挥抑制肿瘤发生作用。然而,在最近Nature的一项研究中,Milanovic等人的研究结果挑战了这种传统观点,该研究结果表明衰老可以促进癌症再发和增强肿瘤侵袭性。 这一发现表明抗衰老药物或许可以应用于抗肿瘤治疗当中。

过去的理论认为,细胞衰老主要发挥抑制肿瘤发生作用。然而,在最近Nature的一项研究中,Milanovic等人的研究结果挑战了这种传统观点,该研究结果表明衰老可以促进癌症再发和增强肿瘤侵袭性。 这一发现表明抗衰老药物或许可以应用于抗肿瘤治疗当中。

年龄是癌症的主要危险因素,因此,预防老龄化的发展可能会阻止癌症的发生。衰老的某些特征也会在细胞中发生。一方面,衰老是一种有效的抑制肿瘤的机制。这是由细胞周期阻滞程序和诱导免疫介导的。然而另一方面,衰老细胞在衰老组织中积累,阻碍组织更新并导致年龄相关性癌症有关的慢性炎症的发生。因此,衰老的选择性干预是目前重要的生物医学目标。

在Milanovic等人最近的一项研究中,揭示了衰老的一个新特征:衰老出乎意料地与高度侵袭性肿瘤有关。这一新发现拓宽了人类对衰老生物学的理解,对癌症治疗具有重要意义,并提出了干预衰老对健康有益的另一个原因。

Milanovic等人比较了衰老和非衰老细胞中的基因表达谱,发现成人组织干细胞标记富集于衰老细胞当中。他们发现这在多种衰老模型中均适用,包括复制性衰老和应激诱导衰老。因此,与已建立的细胞周期停滞,衰老相关性干细胞是衰老的新共同特征。最近研究结果共同表明这种干细胞可能是产生高度侵袭性和恶性肿瘤起始的一种关键机制。

事实上,表观基因组重组被认为是诱导多能干细胞产生的中心事件。此外,衰老细胞必须克服细胞周期停滞和缩短的端粒以转化为功能性干细胞。启动衰老相关干细胞程序的机制是未来研究的一个有趣的课题。理解衰老细胞在细胞周期阻滞和成为干细胞之间的“选择”将是揭示衰老计划的奥秘的关键,并将为肿瘤抑制和进展提供关键的新知识。


药物诱导性衰老可促进癌细胞起始及诱导肿瘤复发

目前的研究为未来在肿瘤发生和癌症治疗中对衰老性干细胞的研究铺平了道路。虽然细胞周期阻滞具有重要的生物学意义,但衰老性干细胞的生理功能仍然未知。虽然未来的研究需要明确衰老性干细胞潜在的生理功能,Milanovic团队清楚地阐明,在癌症治疗的背景下,衰老性干细胞具有产生高度侵袭性肿瘤起始细胞的可能性,这有助于肿瘤复发。

原始出处:

Zhixun Dou,et al. Senescence Elicits Stemness:A Surprising Mechanism for Cancer Relapse.Cell Metab.2018 Apr 3;27(4):710-711.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-05-30 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-09-05 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-10-09 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1960825, encodeId=65281960825bf, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed May 30 08:04:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870556, encodeId=bb5a18e055671, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Apr 30 13:04:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887873, encodeId=e282188e87311, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 05 08:04:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896314, encodeId=402218963144f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Oct 09 06:04:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425299, encodeId=64341425299c7, content=<a href='/topic/show?id=7eb6e134273' target=_blank style='color:#2F92EE;'>#癌症复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71342, encryptionId=7eb6e134273, topicName=癌症复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fad3959854, createdName=lq0302, createdTime=Fri Apr 13 12:04:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305072, encodeId=c9c33050e2b8, content=学习了谢谢了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPeNmuNF9ibgMfMOAs7Iic5MpiaU8RLmRH67xCKuk5wzfhb7G4ib7ia6z9lrnsTicj1nAUfEOMecZDtvvu/0, createdBy=d7f91939785, createdName=186****0580(小山羊), createdTime=Thu Apr 12 09:35:13 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 186****0580(小山羊)

    学习了谢谢了

    0

相关资讯

NEUROBIOL AGING:为什么老了以后睡眠变差

生理昼夜节律的健康是构成身体健康的重要部分。人们发现,老化过程对驱动昼夜生理的系统会产生负面影响,典型的症状与异常/中断的睡眠模式相关。

PLOS ONE:绿茶提取物缓解肌萎缩

含有表没食子儿茶素没食子酸酯等多酚的绿茶提取物(GTE)对肥胖症,高血糖症和胰岛素抵抗有益,但它们对肌肉萎缩的作用仍不清楚。

NAT COMMUN:临床试验证明小分子可能改善心血管衰老

最近,来自科罗拉多大学博尔德分校的研究人员在一个2×6周的随机,双盲,安慰剂对照,交叉临床试验中找到了证据。

Cell & Ann N.Y. Acad Sci:延长寿命、抵抗癌症!少吃这种氨基酸,健康益处良多

最新发表在Cell杂志上的一项成果证实,限制含硫氨基酸的饮食策略能够在小鼠中触发新血管的形成。该发现有望用于延缓衰老、改善血管疾病以及阻止肿瘤生长。让人振奋的是,不久前发表的一篇综述还表示,饮食中限制含硫氨基酸给动物带来的长寿和健康益处,非常有希望能够转化到人类中。

J Cogn Enhanc:冥想能持续提升认知能力

根据发表在《Journal of Cognitive Enhancement》上的一项新研究,通过加强冥想练习获得的注意力保持能力的提升可以维持到七年以后。该研究基于沙玛莎项目(Shamatha Project),这是一个研究冥想对认知、心理和生物学影响的项目,由美国加州大学戴维斯分校思维和大脑中心的研究人员完成。

Cell Stem Cell:中科院科学家首次发现“返老还童”密码

中国科学院广州生物医药与健康研究院(下称中科院广州生物院)研究院裴端卿及其团队,经过 5 年时间,研究通过化学方式,诱导细胞回到年轻状态的方法。实验中,通过制备“魔法药水”,给实验细胞“洗澡”,改变其化学结构,就能控制细胞命运转变方向。

Baidu
map
Baidu
map
Baidu
map